✨ Free AI Report
ARCA biopharma, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research ARCA biopharma, Inc.
Company Research

ARCA biopharma, Inc.: Business Overview, Financials & Competitive Analysis

ARCA biopharma is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. The Company's...

Analyst-debate audio for ARCA biopharma, Inc.

AskCyborg analysts argue the bull and bear cases for ARCA biopharma, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
4/ 10Mixed

Cyborg Score thesis

Speculative precision medicine play dependent on clinical success of genetically-targeted Gencaro and ability to secure...

Read the full analyst-debate transcript →
Industry Cardiovascular Drugs
4 named competitors
1 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 16, 2026
AI-Generated Research
30+ Page Report

Get the Latest ARCA biopharma, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

ARCA biopharma, Inc. Overview

Pro stress-test →

ARCA biopharma is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride) for the treatment of atrial fibrillation (AF) in patients with chronic heart failure (HF).

Strategic Profile

Pro stress-test →

ARCA was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. ARCA has identified genetic variations in cardiac receptors that it believes may predict individual patient response to Gencaro, giving Gencaro the potential to be the first genetically-targeted prevention treatment for AF.

Competitive Landscape

Pro stress-test →

ARCA competes within the cardiovascular disease therapeutics and precision medicine segments. Direct competitors include other precision medicine and genetically-targeted therapy developers focused on cardiac conditions, as well as larger pharmaceutical companies with cardiovascular portfolios. As a clinical-stage company without FDA approvals, ARCA faces significant competitive pressure from established players with approved therapies and greater financial resources.

Industry Context

ARCA biopharma, Inc. operates in Cardiovascular Drugs.

Key facts

Founded: 1992 · Headquarters: Westminster, Colorado, US · Employees: 25 · Revenue: $4 million · Market cap: N/A

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on ARCA biopharma, Inc..

  • ARCA operates as a clinical-stage biopharmaceutical company with a precision medicine approach to cardiovascular disease therapy development
  • Company operates with approximately 25 employees and $4 million in reported revenue
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • May 2022Initiated formal strategic review process to evaluate merger, sale, or other alternatives to maximize shareholder value
Get alerted when ARCA biopharma, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Compare ARCA biopharma, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

ARCA biopharma, Inc. operates in Cardiovascular Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Cardiovascular Drugs research →
NEW · MCP server

Ask your AI assistant about ARCA biopharma, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare ARCA biopharma, Inc. and its top competitor on Cyborg Score”
“What did ARCA biopharma, Inc. do this quarter?”
“Is ARCA biopharma, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does ARCA biopharma, Inc. do?+
ARCA biopharma is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. The Company's...
What is ARCA biopharma, Inc.'s Cyborg Score?+
ARCA biopharma, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are ARCA biopharma, Inc.'s main competitors?+
Named competitors include Lexeo Therapeutics, Tenaya Therapeutics, Akcea Therapeutics, Videregen Biotechnology. The full competitive landscape is in the AskCyborg report.
How can I get the full ARCA biopharma, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the ARCA biopharma, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track ARCA biopharma, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual